Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.

Archives of pharmacal research - 1 Nov 2003

Lee Sukhyang, Kim Jae-Moon, Chung Chin-Sang, Cho Kyoung Joo, Kim Jeong Hee

Abstract excerpt

Cytochrome P4502C9(CYP2C9) is largely responsible for terminating anticoagulant effect by hydroxylation of S-warfarin to inactive metabolites. Mutations in the CYP2C9 gene result in the expression of allelic variants, CYP2C9*2 and CYP2C9*3 with reduced enzyme activity compared to wild type CYP2C9*1. The aim of this study was to assess relationship between requirement of warfarin dose and polymorphism in CYP2C9 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Chi-Square Distribution

Share to Cytochrome P-450 CYP2C9

Share to Prothrombin Time

Share to Warfarin

Source

Identifiers

PMID: 14661864
DOI: 10.1007/BF02980207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.PMID 14661864Read ↗

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.Semantic proximity Read ↗

CYP2C19 polymorphism in Korean patients on warfarin therapy.Semantic proximity Read ↗

Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.Semantic proximity Read ↗

Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.Semantic proximity Read ↗

The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.Semantic proximity Read ↗

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.Semantic proximity Read ↗

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.Semantic proximity Read ↗

Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.Semantic proximity Read ↗

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.Semantic proximity Read ↗

The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.Semantic proximity Read ↗

Warfarin dosing and cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.